Alector LLC, a San Francisco, CA-based biotech company, closed a Series A financing of undisclosed amount.
The round was led by Polaris Venture Partners and OrbiMed Advisors. In conjunction with the funding, General Partner Terry McGuire (Polaris) and General Partner Carl Gordon (OrbiMed) joined Alector’s Board of Directors.
The company intends to use the funds to begin research and development on innovative targets.
Alector is dedicated to the discovery and development of novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. It is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months.
Its founding team includes:
– Arnon Rosenthal, Ph.D. (President and CEO), Rinat Co-Founder and CSO;
– Tillman Gerngross, Ph.D., Dartmouth College Professor (Chairman of the Board),
– Asa Abeliovich, Ph.D., Columbia University Associate Professor, and
– Errik Anderson, Adimab COO.